KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) EBT Margin (2016 - 2025)

Historic EBT Margin for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to 39.76%.

  • Rigel Pharmaceuticals' EBT Margin rose 173000.0% to 39.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 40.53%, marking a year-over-year increase of 380700.0%. This contributed to the annual value of 10.24% for FY2024, which is 317100.0% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its EBT Margin stood at 39.76% for Q3 2025, which was up 173000.0% from 58.99% recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year EBT Margin high stood at 58.99% for Q2 2025, and its period low was 164.0% during Q1 2022.
  • Over the past 5 years, Rigel Pharmaceuticals' median EBT Margin value was 20.23% (recorded in 2023), while the average stood at 24.32%.
  • Over the last 5 years, Rigel Pharmaceuticals' EBT Margin had its largest YoY gain of 1139600bps in 2022, and its largest YoY loss of -2149400bps in 2022.
  • Rigel Pharmaceuticals' EBT Margin (Quarter) stood at 111.23% in 2021, then skyrocketed by 102bps to 2.73% in 2022, then decreased by -25bps to 2.06% in 2023, then surged by 1184bps to 26.43% in 2024, then soared by 50bps to 39.76% in 2025.
  • Its last three reported values are 39.76% in Q3 2025, 58.99% for Q2 2025, and 21.58% during Q1 2025.